JPM22, Day 3: Eli Lilly weighs dual branding for diabetes hopeful tirzepatidenews2022-01-12T13:12:43+00:00January 12th, 2022|Fierce Pharma|
JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launchnews2022-01-12T13:12:43+00:00January 12th, 2022|Fierce Pharma|
UPDATED: JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launchnews2022-01-12T13:12:43+00:00January 12th, 2022|Fierce Pharma|
Pfizer offers a soft sell but with a strong message on vaccines in first COVID adnews2022-01-12T13:05:02+00:00January 12th, 2022|Fierce Pharma|
Pfizer offers a soft sell with a strong message on vaccines in first COVID adnews2022-01-12T13:05:02+00:00January 12th, 2022|Fierce Pharma|
For Biogen’s Aduhelm, narrow coverage from CMS ‘could effectively spell the end’: analystnews2022-01-12T12:18:38+00:00January 12th, 2022|Fierce Pharma|
JPM 2022: Eli Lilly gears up for Alzheimer’s-diabetes juggling act as 2 key FDA decisions loomnews2022-01-12T11:53:03+00:00January 12th, 2022|Fierce Pharma|
Pfizer takes the ax to US sales reps amid virtual pushnews2022-01-12T10:39:36+00:00January 12th, 2022|Fierce Pharma|
JPM 2022: Eli Lilly CEO mulls using Novo’s double-branding trick on tirzepatide—one obesity, one diabetesnews2022-01-12T08:07:38+00:00January 12th, 2022|Fierce Pharma|
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15Bnews2022-01-11T22:56:55+00:00January 11th, 2022|Fierce Pharma|
